Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. brain imaging
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Magazines
Videos

Refine by
Date

  • This Year
  • Older

Brain Imaging Articles & Analysis

23 news found

Ace Therapeutics Accelerates Preclinical Depression Investigation by Providing Depression-Related Behavior Tests

Ace Therapeutics Accelerates Preclinical Depression Investigation by Providing Depression-Related Behavior Tests

Ace Therapeutics, a preclinical contract research provider dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests in its preclinical investigation processes. This integral development aims to enhance the understanding of depressive disorders and ...

ByAce Therapeutics


Synaptive Medical to Test New Software for Brain Surgery Planning at Unity Health Toronto

Synaptive Medical to Test New Software for Brain Surgery Planning at Unity Health Toronto

Planning brain surgery is a delicate process that requires precision to avoid damaging surrounding brain tissue and to prevent post-surgery complications. Synaptive Medical, a leader in medical technology, is set to enhance this process by evaluating its new software called Modus Plan, at Unity Health Toronto’s St. Michael’s Hospital, with support from OBIO’s Life Sciences ...

BySynaptive Medical


SpinTech CEO Presents STAGE at MedTech Strategist Innovation San Francisco 2021

SpinTech CEO Presents STAGE at MedTech Strategist Innovation San Francisco 2021

Ward Detwiler, our President & CEO, had the opportunity to speak about how STAGE is innovating the world of MR at MedTech Strategist Innovation 2021. ...

BySpinTech, Inc.


Pivalate’s additional data released from positive Phase II imaging trial in brain metastases

Pivalate’s additional data released from positive Phase II imaging trial in brain metastases

Sydney, Australia - November 23, 2022 - Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Imperial College London has released additional data related to the F-18 Pivalate (RAD 101) Phase 2a imaging trial in patients with brain metastases. High contrast images (see below) ...

ByRadiopharm Theranostics


Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association

Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: The Journal of the ...

ByLongeveron, Inc.


Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses

Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses

Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. Inscopix offers innovative miniature-microscope (miniscope) based imaging ...

ByInscopix Inc.


Qynapse to Present New Evidence on the Value of QyScore for the Diagnosis and Monitoring of Multiple Sclerosis at ACTRIMS Forum 2022

Qynapse to Present New Evidence on the Value of QyScore for the Diagnosis and Monitoring of Multiple Sclerosis at ACTRIMS Forum 2022

BOSTON, MA, February 14, 2022, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to present 2 posters at the annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, on February 24-26, in West Palm Beach, FL. The posters ...

ByQynapse


AI ‘Fingerprinting’ Fights Back Against Hard-to-Detect Cancers

AI ‘Fingerprinting’ Fights Back Against Hard-to-Detect Cancers

Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. Reveal Surgical is working on changing that reality through its new, AI-based Sentry technology, which leverages a combination of AI and Raman spectroscopy to provide real-time tissue diagnostics during surgery for otherwise-invisible ...

ByReveal Surgical


Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)

Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)

A collaborative research initiative supported by ADDF’s Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to advance the most promising early diagnostics for Alzheimer’s disease. Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease ...

ByOptina Diagnostics


M Health Fairview University of Minnesota Medical Center Receives First Hyperfine Portable MRI to Grow its Advanced Imaging Systems Offering

M Health Fairview University of Minnesota Medical Center Receives First Hyperfine Portable MRI to Grow its Advanced Imaging Systems Offering

Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine”), creator of the first U.S. Food and Drug Administration (“FDA”) cleared portable magnetic resonance imaging (“MRI”)TM device, Swoop®, is proud to announce that M Health Fairview is deploying a Swoop system in the emergency room (ER), intensive care unit (ICU) and post anesthesia environments at M Health Fairview ...

ByHyperfine


Another good news for Deep01! Taiwan`s first AI product obtained marketing approval from Japan`s FDA

Another good news for Deep01! Taiwan`s first AI product obtained marketing approval from Japan`s FDA

DeepCT - Intracranial Hemorrhage (ICH) AI Detection Software - developed by Taiwan's high-profile AI start-up team Deep01 - has obtained the marketing approval of Japan's PMDA, which is the first deep learning software officially licensed by Japan in Taiwan , marking a new milestone in Taiwan's AI medical output. Japan has the world's most aging population, and with advanced medical development, ...

ByDeep01 Limited


Hyperfine Closes Business Combination with HealthCor Catalio Acquisition Corp and Liminal Sciences, Will Begin Trading under the Ticker “HYPR” on the Nasdaq Global Market

Hyperfine Closes Business Combination with HealthCor Catalio Acquisition Corp and Liminal Sciences, Will Begin Trading under the Ticker “HYPR” on the Nasdaq Global Market

Business combination results in over $160 million in gross cash proceeds to Hyperfine Funds to catalyze commercial expansion of the world’s first FDA-cleared portable MRI systemTM and additional organic growth initiatives Hyperfine to begin trading on Nasdaq under ticker “HYPR” Hyperfine Inc., the groundbreaking medical device company that created Swoop®, the ...

ByHyperfine


Optina Diagnostics Closes an Oversubscribed Series-A Round of CA$24.8 million

Optina Diagnostics Closes an Oversubscribed Series-A Round of CA$24.8 million

2021 Optina, an innovative diagnostics company leading the field of Retinal Imaging, Brain Health and Systemic Diseases Diagnostics, announced today the closing of an CA$24.8 million Series A round of funding. Optina’s Retinal Deep Phenotyping™ platform obtained FDA Breakthrough Device Designation status in 2019 for its non-invasive and more accessible test to improve diagnosis ...

ByOptina Diagnostics


Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes

Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes

Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared to previous therapy 40% of patients experienced exceptional responses lasting at least three ...

ByExscientia


Oxford Brain Diagnostics establishes a research-based clinical MRI study in Japan to investigate how Cortical Disarray Measurement (CDM) analysis may support differential diagnosis and estimate disease severity in Dementia patients

Oxford Brain Diagnostics establishes a research-based clinical MRI study in Japan to investigate how Cortical Disarray Measurement (CDM) analysis may support differential diagnosis and estimate disease severity in Dementia patients

Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have established a research collaboration with Principal Investigator Dr Takashi Nakajima, MD, PhD at Niigata Hospital and Dr Kazuo Shigematsu at Minami Kyoto National Hospital. In Japan, clinical MRI scanners are available for ...

ByOxford Brain Diagnostics Ltd.


How the brain-eye connection aims to make memory loss a souvenir

How the brain-eye connection aims to make memory loss a souvenir

In fact, nearly 40% of people over the age of 65 suffer from some form of memory loss. Understanding the causes of memory loss There’s currently no cure for Alzheimer’s or Alzheimer’s related dementia, early detection can give patients more control over how they manage their overall well-being. That includes managing their brain health to reduce certain risk factors, ...

ByOptina Diagnostics


FUJIFILM VisualSonics Celebrates the First Installation of the Vevo F2 with Photoacoustics

FUJIFILM VisualSonics Celebrates the First Installation of the Vevo F2 with Photoacoustics

FUJIFILM VisualSonics Inc., a world leader in ultra-high frequency ultrasound and photoacoustic imaging systems, and subsidiary of FUJIFILM SonoSite, Inc., recently celebrated the first installation of the new Vevo F2 imaging platform with photoacoustics at the Université de Tours, Tours, France, thanks to financial contributions from Région Centre Val de Loire and European Union. ...

ByFUJIFILM VisualSonics, Inc.


MassChallenge announces 30 digital health companies to join its 2019 cohort

MassChallenge announces 30 digital health companies to join its 2019 cohort

At the end of the program the startups will get a chance to compete for more than $200,000 in prize money. Last week MassChallenge HealthTech unveiled the 30 digital health startups that will make up its 2019 cohort. The program gives the startups co-working office space and a tailored curriculum, with the primary goal of connecting startups to advisors, investors, pilots and research ...

ByEpihunter NV


NFL & GE Announce Six Final Winners of $10 Million Head Health Challenge

NFL & GE Announce Six Final Winners of $10 Million Head Health Challenge

Innovations are advancing the understanding and diagnosis of mild traumatic brain injury Breakthrough ideas include: point-of-care blood test to rapidly detect the presence of mild and moderate brain trauma; biomarkers that indicate how the brain reacts following a traumatic brain injury (TBI) and a method to identify which brain areas become disconnected after injury GE (NYSE: GE) and the ...

ByGeneral Electric


Prenatal exposure to insecticide Chlorpyrifos linked to alterations in brain structure and cognition

While No Longer Registered for Household Use in the U.S., the Insecticide Is Widely Used Around the World and in U.S. Agriculture Even low to moderate levels of exposure to the insecticide chlorpyrifos during pregnancy may lead to long-term, potentially irreversible changes in the brain structure of the child, according to a new brain imaging study by researchers from the Columbia Center for ...

ByNational Institute of Environmental Health Sciences (NIEHS)

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT